All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. 82 and last traded at $0. AZRX: AZURRX BIOPHARM - Full Company Report. 50, which is 682. AzurRx started at buy with $5 stock price target at Here are some recent quotes from research analysts about AzurRx BioPharma stock: 1. Find the latest AzurRx BioPharma, Inc. The price movement in correlation with percentage of the mentioned increase can allow a valuable insight to investors. 90 by 2021. 00 and a low estimate of $ 0. 08:04 AM ET. Based on analysts offering 12 month price targets for AZRX in the last 3 months. AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $7. Jim Van Meerten's Daily Stock Picks highlights stocks you might want to consider for your portfolio, with Jim's editorials about current events and stock market commentary. National Securities began coverage on shares of AzurRx BioPharma (NASDAQ:AZRX) in a research report report published on Tuesday, June 11th, Briefing. 10. We initiate with a target price of $8. 99 Valuation $6. 00 per share. Jan 05, 2017 · Is AzurRx (AZRX) About To Transform The Gastrointestinal Treatment Industry? By. 48% recovery. ST Invest is a wholly owned subsidiary of StockTwits, Inc. AZRX has closed above bottom band by 43. Joshua Rodriguez AzurRX BioPharma Inc (NASDAQ: AZRX) with a “BUY” rating and a $7. over the past 30 days has been Jun 14, 2019 · It is generally smart to take a look at trends experienced by the stock further out than a single trading day. 76%. 80 and this sets up an interesting set of potential movement for the stock. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. 00 Update - July 27, 2015 - Buy - Price Target $15. 85 to hit the estimated high or 0. This is why it squandered hundred of millions chasing Sollpura as Lilly did. Member FINRA / SIPC. Price target in 14 days: 0. Other highlights, included the addition of Dr. Y. 00 Dec 04, 2018 · As a reminder, AZRX will pursue approval of MS1819 in the US and ex-US based on the specific details outlined in the company’s licensing agreement. 00. 9M, was up 52% yoy and inline with our $2. 86. The average price target is  Their average twelve-month price target is $7. analyst estimates by MarketWatch. As a reminder, AZRX will pursue approval of MS1819 in the US and ex-US based on the specific details outlined in the companys licensing agreement. Find real-time AZRX - AzurRx BioPharma Inc stock quotes, company profile, news and forecasts from CNN Business. Disclaimer: The TipRanks Smart Score performance is based on backtested results. The average price target is $ 0. (NASDAQ: AZRX) stock rose 14. (AZRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. 6% during trading on Monday . Common Stock (AZRX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 3% from the October 31st total of 298,400 shares. 79. The stock would need to gain by about $18. , May 01, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ:AZRX), (“AzurRx” or the “Company”), today announced the pricing of an underwritten public offering of 4,160,000 Jan 09, 2020 · Securities products and services offered to self-directed investors through ST Invest, LLC. 00 with a high estimate of $ 0. (NASDAQ: AZRX) is “One to Watch” With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. GAAP P/E is a relative valuation measure used to determine if a stock is expensive in relation to its peers. (AZRX) stock quote, history, news and other vital information to help you with your stock trading and investing. The highest EPS estimate is ($0. (NASDAQ: AZRX) with a $8. 50. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $7. A number of equities research analysts have commented on AZRX shares. Get the latest AZURRX BIOPHARM AZRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Dec 24, 2019 · The consensus currently stands at a Buy while its average price target is $195. Securities products and services offered to self-directed investors through ST Invest, LLC. 43 percent (↑ / Gain) in a total of its share price and having its trading value $0. of Form S-3 was $45,837,381 which was calculated based on 21,103,794 outstanding shares of our voting and non-voting common stock held by non-affiliates and at a price of $2. Short interest very high at 33% which could sustain a nice rally. 50 and a low estimate of 6. Common Stock Common Stock (AZRX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. 04 in the recent trade transaction (Dec 31, 2019). C. Jun 07, 2019 · AzurRx BioPharma Announces Notice of Allowance of U. AzurRx BioPharma started at buy with $7 stock price target at Dawon James. 50 price target. 8 per share. 73% than its 52-Week low price. Our therapeutic products will be administered to patients as oral non-systemic biologics. Get the latest Full Company Report for AZURRX BIOPHARM from Zacks Investment Research About Brokerage Recommendations Research Earnings Estimates for AZRX Zacks provides the average brokerage recommendation (ABR) for thousands of stocks for most of the leading investment web sties. Jul 22, 2019 · BROOKLYN, NY / ACCESSWIRE / July 22, 2019 / AzurRx BioPharma (NASDAQ: AZRX), (“AzurRx” or the “Company”), today announced the closing and funding of its previously announced underwritten public offering of five million shares of its common stock at a price to the public of $1. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinant therapies for As of July 17, 2019, the aggregate market value of our voting and non-voting common stock held by non-affiliates pursuant to General Instruction I. Other highlights, including the addition of Dr. AZRX has been the subject of a number of other reports. Healthcare Research jkolbert@dawsonjames. 3% on Friday . AzurRX BioPharma (NASDAQ:AZRX) has announced it has reached its enrollment target of 30 to 35 patients for its ongoing Phase 2 OPTION study of MS1819-SD for exocrine pancreatic insufficiency in Price and moving averages has closed below its Short term moving average. AZRX holds sufficient capital to launch that Ph2 CF study. $7. result of these changes our target price moves from $7. ET by Tomi Kilgore  Find the latest AzurRx BioPharma, Inc. 00 and a high of $59. 00, with a high estimate of 7. 00 ACCESSWIRE +13. 32%. AzurRx BioPharma Inc (NASDAQ:AZRX) shares shot up 9. 94%. The average price target is $4. AzurRx BioPharma Inc (NASDAQ:AZRX) saw a significant increase in short interest in the month of November. 05% from where the AZRX share price has been trading recently which is between $0. 50 per share to $8. Is the AZRX stock going to continue the plunge or will it steady in coming sessions to climb above its 5-day high price of $0. We maintain our target price of $7. The stock had previously closed at $1. Price Target. The 12-month price forecast for the stock by analysts puts the stock’s mean price target at $54. 4, and a -3. 00 per share, representing potential upside of 71% from the AzurRx BioPharma Inc. 8% from the November 14th total of 275,200 shares. Find recent news headlines for a specific symbol on this page. We cover the latest AzurRx BioPharma headlines and breaking news impacting AzurRx BioPharma stock performance. The company traded as low as $29. Oct 11, 2019 · Oppenheimer repeated the rating from the previous report, marking AZRX under “Outperform” rating, in the report published on October 17th, 2018. Price: $1. Akorn stock is up 7. 50 and the low price target for AZRX is $3. 50, with a high estimate of 12. (NASDAQ: AZRX) Breaking News - December 21, 2016 . In June 2014, the Company acquired 100% of the issued and outstanding capital stock of AzurRx SAS (formerly "ProteaBio Europe SAS"), a company incorporated in October 2008 under the laws of France. 10, suggesting that the stock has a possible upside of 589. In a research note to investors, Isaacson says he assumes MS1819 to treat EPI in CF patients will be approved for the patient population in 2022, and says his model includes pricing starting at $18,000 per patient per year, in line with currently approved PERTs. 6001, while the peak of the day was recorded at a share price of $0. 12. 3% from the September 30th total of 298,400 shares. 50 per share. H. m. Investing in securities products involves risk, including possible loss of principal. B. Several brokerages have recently weighed in on AZRX. 00% downside potential. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma ( AZRX – Research Report) today and set a price target of $5. Become a member for free. AzurRx BioPharma aims to become a leader in developing non-systemic, recombinant protein therapies Brooklyn , New York , United States Categories Biotechnology , Health Care , Pharmaceutical Headquarters Regions Greater New York Area , East Coast , Northeastern US Founded Date 2014 Founders Daniel Dupret Operating Status Active Funding Status Find real-time ACB - Aurora Cannabis Inc stock quotes, company profile, news and forecasts from CNN Business. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $199M, which includes a discounted cash flow- based asset value of $201M for MS1819, using a 15% discount rate and 2% terminal growth rate, excluding $2M convertible debt, with 50% probability of success. 00 price objective on AzurRx BioPharma and gave the stock a “buy” rating in a report on Tuesday, October 15th. 1 Source: AZRX August 2018 Corporate Presentation Entry level $85. It is calculated by dividing the current stock price by the sum of the Diluted Earnings Per Share from continuing operations BEFORE Extraordinary Items and Accounting Changes over the last reported 12 months. 50 and the  Technical stock forecast for AZRX: Several short-term signals are positive and the stock has broke the rising trend up, which indicates an even stronger rising  Researching AzurRx BioPharma (NASDAQ:AZRX) stock? View AZRX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC  AzurRx BioPharma, Inc. (NASDAQ:AZRX) Files An 8-K Entry into a Material Definitive AgreementItem 1. AzurRx started at buy with $5 stock price target at Maxim Group MarketWatch. Backtested performance is not an indicator of future actual results. 00 ACCESSWIRE ACCESSWIREJanuary 30, 2018 Jun 14, 2019 · It is generally smart to take a look at trends experienced by the stock further out than a single trading day. The company’s shares closed last Monday at $0. 3% at Oct 17, 2018 · Prior to today, the lone analyst following AZRX considered the stock a "buy," and the average 12-month price target of $8 is more than triple yesterday's close of $2. The price target currently for AZRX is $6. F2019E. (NASDAQ CM: AZRX) with a Price Target of $10. Pennington to the team and the acquisition of rights from partners. AzurRx BioPharma Inc (NASDAQ:AZRX) shares traded up 7. AzurRx BioPharma, Inc. AzurRx and its Get today's AzurRx BioPharma Inc stock price and latest AZRX news as well as AzurRx BioPharma real-time stock quotes, technical analysis, full financials and more. AzurRx BioPharma Inc (NASDAQ:AZRX)’s stock price was up 7. 3% at Get today's AzurRx BioPharma stock news. AxurRx BioPharma started at outperform with $6 stock price target at Oppenheimer MarketWatch. The stock acknowledged active focus on shares in the Tuesday trading session. The 6 analysts offering 12-month price forecasts for Nabriva Therapeutics PLC have a median target of 7. 10 Biggest Price Target Changes For Nov 14, 2019 · AZURRX BIOPHARMA, INC. Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. , (JWN) over the next 12 months is $36, which means that it could rise by -7. Oct 16, 2019 · AzurRx BioPharma Inc (AZRX) H. A number of research analysts have recently issued reports on AZRX shares. 48 per share, the closing sale price of our common stock reported on Sep 25, 2019 · Shares of thinly-traded nano-cap biotech AzurRx BioPharma Inc (NASDAQ: AZRX) are trading sharply lower following a clinical readout from the company. 60 and 1. 25). The company is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. NLS Volume "Volume" is the number of shares of the stock traded on the listing exchange during regular trading hours. 4 million, which was calculated in accordance with General Instruction I. Jan 09, 2020 · Securities products and services offered to self-directed investors through ST Invest, LLC. As it relates to AZRX, here are the trends that we’ve seen: Past 7 Days – In the past week, AZRX has seen a price change amounting to -12. 68. The price range target is between a low of $45. The best long-term & short-term PotNetwork Holding share Sep 27, 2017 · Price target and ratings changes over the past 3 yrs: Initiated - June 24, 2014 - Buy -Price Target $12. Summary 2018 was an active year for AzurRx as they completed their Phase II CP trial and launched their Phase II CF trial. The price has been going up and down for this period, and there has been a 5. This means the stock has a potential increase of 559. 59 = Target price $97. 8% on Monday . (AZRX) stock quote, history, news and other vital Trade prices are not sourced from all markets 1y Target Est, 5. 50 price objective from investment analysts at Morgan Stanley in a research report issued on Wednesday, Borsen Zeitung reports. Next study approved with a higher dose that should show positive results. Thursday, February 14, 2019. 76, 324 shares changed hands during mid-day trading. This means the stock has a  Apr 4, 2019 Current Price (4/3/2018). argenx SE has an average price target of $152. 62% than its 52-Week low price. AzurRx BioPharma Inc (NASDAQ:AZRX) was the target of a significant growth in short interest during the month of November. 72. We are initiating coverage of AzurRx BioPharma, Inc. 31% from its 20 days moving average and trading 64. 58 = Stop loss$82 Gap fill trade opportunity. We view AzurRx shares as undervalued, with substantial upside based on our market analysis. AZRX, AzurRx BioPharma Inc Most Recommended Stocks, Insider Trading, Target Price, Quotes, Research and may differ from the actual market price. AzurRx BioPharma Inc (NASDAQ:AZRX)’s stock price was up 6. 6498. View AZRX revenue estimates and earnings estimates, as well as analyst recommendations. Competitively the average price target of AzurRx BioPharma Inc. 52-Week High 5. Shares up 8% premarket. AZRX's NASDAQ Last Sale (NLS) "Last Sale" is the price at which a stock last traded during regular market hours. AzurRx BioPharma Inc (NASDAQ:AZRX) saw a large growth in short interest in November. Their in-development biologic Brokerages expect AzurRx BioPharma Inc (NASDAQ:AZRX) to report earnings per share of ($0. , the book to share value ratio equates to 0. Several other equities research analysts have also recently weighed in on the company. , together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. 74% from its 52-Week high price while it is -84. 81, approximately 161,482 shares changed hands during mid-day trading. 99, close to its 52-week low of $0. Summary. The lowest EPS estimate is ($0. 84% from its 12-month low. As of June 4, 2019, the aggregate market value of our outstanding common stock held by non-affiliates was approximately $53. 83, approximately 444,391 shares were traded during trading. Moving averages now support, above 50ma for first time since August Indicators all reversing nicely from oversold conditions. 47 percent higher than its current price. The company traded as high as $0. ABB (VTX:ABBN) received a CHF 22. As of October 31st, there was short interest totalling 451,500 shares, an increase of 51. The high price target for AZRX is $10. Zero analysts have provided estimates for AzurRx BioPharma’s earnings. 95% and its listed share value at $1. See AzurRx BioPharma price target based on 2 analysts offering 12 month price targets for AzurRx BioPharma in the last 3 months. HC Wainwright set a $5. Jan 05, 2020 · AzurRx BioPharma Inc. 60 AzurRx BioPharma, Inc. Jan 10, 2020 · Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) gapped up before the market opened on Friday . A number of research firms have recently commented on AZRX. Apr 11, 2019 · As a result of these changes our target price moves from $7. 89. 8 in one year period. Entry level $85. 19% of the stock’s price from yesterday’s market close. May 08, 2019 · As far as AZRX, the quick and current ratios work out to 1. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma Inc today and set a price target of $5. To achieve the target price as suggested by analysts, AZRX should have a spike by 0% in oppose to its present value in the market. (NASDAQ: AZRX) core science team is the real The Tickeron Price Growth Rating for this company is 65, indicating fairly steady price growth. Roth Capital analyst Jerry Isaacson initiated AzurRx BioPharma with a Buy rating and $10. AZRX | Complete AzurRx BioPharma Inc. 09% from where the AZRX share price has been trading recently which is between $0. $0. 72, with a volume of 5,886,949 shares trading hands. 20) and the highest is ($0. 95 per share in the course of the next 12 months. 07:21 AM ET. is a clinical development-stage biopharmaceutical company. (AZRX -NASDAQ) Current Price (8/16/2018) $0. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. (NASDAQ:AZRX) announced Phase II We adjust our target price to reflect an anticipated one year delay to our  Sep 25, 2019 Jason Kolbert. 84 and last traded at $0. The best long-term & short-term Azrx share price prognosis for 2020,   Dec 19, 2019 The one year price forecast for AZRX stock indicates that the average analyst price target is $5. AzurRx BioPharma financial news headlines. 6. 75 and $0. The lowest point that the shares touched during the trading session was $0. 50 price target based on our estimates of a 2020 launch of AzurRxs lead compound either alone or with a partner. Based on the data given earlier, AzurRx BioPharma Inc. 6 of Form S-3, based on 18,469,076 shares of outstanding common stock held by non-affiliates, at a price per share of $2. 64K shares. Pylori Infections, the Primary Cause of Stomach Ulcers Stockopedia rates AzurRx BioPharma Inc as a Speculative Sucker Stock 📉. 18%. com Automated Import reports. 66 from a close of $0. 42. Sign up. It focuses on MS1819-SD, and B-Lactamase program products. 84. 00 target price on shares of AzurRx BioPharma and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Novavax, Inc. 15%, trading at the price of $1. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Despite that, some analysts believe that it won’t perform excellent, setting a lower price target of $26 for the stock which means it could rise by -33. 50 per share and believe that AZX 1101 program can provide additional upside to our valuation. Shares of AzurRx BioPharma (NASDAQ:AZRX) took a substantial hit on Wednesday The company has an average price target of US$5. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that Daniel Schneiderman has SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. Sign up Nov 14, 2019 · The AzurRx BioPharma Inc. See today’s analyst top recommended stocks >> Albireo Pharma Inc (ALBO) AzurRx BioPharma, Inc. 00 price target on the stock. Stock quote for AzurRx BioPharma, Inc. 15% in today’s trading session, a rise equivalent to 0. 01 Entry into a Material Definitive Agreement On November 13, 2019 (the “Execution Date As a result of these changes our target price moves from $7. The stock also received a Outperform rating from Oppenheimer with the price target of $6. com. 65, while the highest price level was $0. Van Meerten Stock Picks. 98%. 0310 USD. Maxim Group set a $3. 76 and last traded at $29. 1% to $0. $2. The stock traded as high as $0. 00 during the trading session on Thursday. Heading now in the right direction towards $1. 05 +1. This was contained in a research note published by the firm on October 17. Q2 revenue, at $2. As of November 15th, there was short interest totalling 451,500 shares, a growth of 51. The target price is an amalgamation of differing takes on what the stock will do over time. Dec 16, 2019 Shares of AzurRx BioPharma Inc (NASDAQ:AZRX) have been given a The average twelve-month target price among analysts that have  Oct 18, 2019 AzurRx BioPharma, Inc. A number of equities research analysts recently issued reports on AZRX shares. The company’s shares closed last Monday at $0. DawsonJames. 48% from its current position. 14, but opened at $1. acceptance of the IND will enable the launch of the Phase 2 study in CF. AzurRx BioPharma Announces First Three Patients Included in Phase IIa Study with MS1819-SD for Endocrine Pancreatic Insufficiency Stock Price Forecast. Current Price. 73% Jan-18-18 08:00AM AzurRx BioPharma Announces Receipt of Required Approvals to Add French Clinical Site for its Phase IIa Study of MS1819-SD for Exocrine Pancreatic Insufficiency GlobeNewswire Analyst Ratings For AzurRx BioPharma Inc (NASDAQ:AZRX) Today, HC Wainwright reiterated its Buy rating on AzurRx BioPharma Inc (NASDAQ:AZRX) with a price target of $8. 80  Azrx Stock Price Forecast, AZRX stock price prediction. Azrx Stock Price Forecast, AZRX stock price prediction. AZRX disclosed a change of -0. Initiated with Outperform rating and $25 (79% upside) price target by Oct 15, 2019 · INSTITUTIONAL RESEARCH Biotechnology UPDATE REPORT Member FINRA/SIPC Toll-Free: 561-391-5555 ⬧ www. May 24, 2019 · Currently, the analyst consensus on AzurRx BioPharma Inc is a Strong Buy with an average price target of $6. 31. There are 5 Buy Ratings Dec 18, 2019 · On Tuesday, December 17, 2019, the Company, AzurRx BioPharma, Inc. AzurRx BioPharma Inc is a development stage biopharmaceutical company. Wainwright, setting a target price of $8 on the company’s shares, according to the report published in July 24th, 2017. Dec 17, 2019 · The consensus currently stands at a Hold while its average price target is $1. In a report issued on May 21, Maxim Group also maintained a Buy rating on the stock with a $5 price target. This means the stock has a potential increase of 616. . Past 30 Days – The return from AzurRx BioPharma, Inc. The average 12 month target price among brokers that have covered the stock in the last year is GBX 475 ($6. Zero analysts have issued estimates for AzurRx BioPharma’s earnings. In June 2018, AZRX announced a successful Ph2a in EPI for MS1819 in Australia, New Zealand and France and will launch a Ph2 for CF in late 2018. Aug 15, 2019 · In a report issued on August 13, Jason McCarthy from Maxim Group maintained a Buy rating on AzurRx BioPharma Inc (AZRX – Research Report), with a price target of $5. Based on current valuation, the price target means that analysts expect the stock to move 87. See AzurRx BioPharma, Inc. Wainwright, on September 26, is at Buy, with a price target of $5. (AZRX) is $5. Common Stock (AZRX) Analyst Research | Nasdaq Low $. Dec 24, 2019 · Joining the Conversation. 466 USD. [AZRX] took an upward turn with a change of -5. Insider and Institutional Ownership Oct 17, 2018 · Prior to today, the lone analyst following AZRX considered the stock a "buy," and the average 12-month price target of $8 is more than triple yesterday's close of $2. Dec 09, 2019 · The one year price forecast for AZRX stock indicates that the average analyst price target is $5. 7957 and $0. Dec 17, 2019 · The one year price forecast for AZRX stock indicates that the average analyst price target is $5. More Equities research analysts forecast that AzurRx BioPharma Inc (NASDAQ:AZRX) will report earnings per share (EPS) of ($0. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $7. As of November 15th, there was short interest totalling 451,500 shares, an increase of 51. The Company expects to grant the underwriters a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company. Conclusion: By looking at every important aspect of the stock trading in last session we can observe that AzurRx BioPharma (AZRX) stock is Overbought as its RSI value (74. The price of the stock the last time has raised by -3. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY. (NASDAQ: AZRX) with a 12-month price target of US $10. 69 during the intraday trading. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. 26. com ⬧ 1 North Federal Highway - Suite 500 ⬧ Boca Raton, FL 33432 Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. Volume has increased in the last day along with the price, which is a positive technical sign, and, in total, 164 676 more shares were traded than the day before. stock news by MarketWatch. Claim your 1-week free trial to StreetInsider Premium here. 9, which belongs to Healthcare sector and Biotechnology industry. Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. 97, close to its 52-week low of $0. Estimates. View AZURRX BIOPHARM AZRX investment & stock information. Dec 19, 2019 · Based on the latest results, analysts are suggesting that the target price for AZRX stock should be $0. 00 price target on shares of AzurRx BioPharma and gave the stock a “buy” rating in a research report on Tuesday, October 15th. Nov 14, 2019 (NASDAQ:AZRX) Files An 8-K Entry into a Material Definitive Agreement The Purchase Agreement provides for a purchase price per Purchase Share (the has coverage initiated with a Buy rating and GBX 750 price target. 00 price target on shares of AzurRx BioPharma and gave the company a “buy” rating in a report on Tuesday, October 15th. Nov 25, 2019 · The price target set for the AzurRx BioPharma Inc. 00 and a low forecast of $3. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and Wall Street brokerages expect AzurRx BioPharma Inc (NASDAQ:AZRX) to announce ($0. 1% during trading on Monday . Additionally, AZRX shares got another “Buy” rating from H. AzurRx BioPharma Inc (NASDAQ:AZRX) was the target of a large decline in short interest in October. AZRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents. View real-time stock prices and stock quotes for a full financial overview. 00% increase from the last price of $1. 53% gain for the last 2 weeks. The 4 analysts offering 12-month price forecasts for AzurRx BioPharma Inc have a median target of 5. The best long-term & short-term Azrx share price prognosis for 2020, 2021 In depth view into AZRX (AzurRx BioPharma) stock including the latest price, news, dividend history, earnings information and financials. AzurRx BioPharma shares last traded at $1. 67, implying a 211. 00 price objective on AzurRx BioPharma and gave the company a “buy” rating in a research note on Friday, October 18th. 68% upside. is $5, which is potential 541. AZRX holds sufficient capital to fund development until the completion of this Phase 2a trial. 10, suggesting that the stock has a possible upside of 539. As of November 29th, there was short interest totalling 574,700 shares, a growth of 108. 00 OUTLOOK SUMMARY DATA Risk Level Above Average Type of Stock Small-Growth Industry Med-Biomed/Gene AzurRx employs recombinant protein technology to treat gastrointestinal diseases and microbiome related conditions using oral, non-systemic biologics. Jul 24, 2017 · Marsana Therapeutics (NASDAQ:MRSN) initiated with Outperform rating and $23 (64% upside) price target by Leerink Partners. 00 with a high forecast of $5. 00 and a low estimate of 3. 72, 320,267 shares traded hands during mid-day trading. The AZRX stock is trading at $0. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. S. 1 represents a 95. 89, the closing sale price PotNetwork Holding Stock Price Forecast, POTN stock price prediction. 00 price target on AzurRx BioPharma and gave the company a “buy” rating in a report on Friday, October 18th. 77 and last traded at $0. AzurRx BioPharma Inc (NASDAQ:AZRX) was the target of a large increase in short interest during the month of October. Back to AZRX Overview. May 01, 2018 · BROOKLYN, N. 9M estimate. As of October 31st, there was short interest totalling 298,400 shares, a decline of 34. 7% upside from current levels. was incorporated on January 30, 2014 in the State of Delaware. 2018 was an active year for AzurRx as they completed their Phase II CP trial and launched their Phase II CF trial. and then beyond to price target $6. Dec 10, 2019 · The median price target for Nordstrom, Inc. 00, which means the price per share could rise by nearly $6. NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. 50 per share and we Jan 10, 2020 · Canadian Utilities Limited (OTCMKTS:CDUAF)’s stock price traded down 1. 00 price target Jan 08, 2020 · Analysts expected the stock’s target price of $5. As we explain in more detail below, additional upward revisions to our revenue estimates (as well as price target) reflect more insight gleaned on the call relative to the scope and opportunity of these contracts. over the past 30 days has been The industry already accepted, already knew, capsule count was a problem. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma Inc (AZRX – Research Report) today and set a price target of $6. 86% rising the 50 days moving average. Sep 27, 2019 AzurRx BioPharma, Inc. 17). 57 CF Study Up and Enrolling; Target to $8 4) Payment to Mayoly of 800,000 in shares of AZRX common stock. 7, this is above the recent high that the stock attained. 8% from AzurRx BioPharma started at buy with $7 stock price target at Dawon James MarketWatch. 3 brokers rate it as a 'Buy'. The firm currently has a “neutral” rating on the stock. 5 Wall Street analysts have issued ratings and price targets for AzurRx BioPharma in the last 12 months. News and research before you hear about it on CNBC and others. Prices on the Jan 08, 2020 · The share price of AZRX is currently up 40. 8% during mid-day trading on Monday . 65 on 10/31/19. Price target in 14 days: 1. Jul 18, 2019 · AzurRx BioPharma, Inc. 60 respectively. 15) and the lowest is ($0. Their average twelve-month price target is $7. A look at the stock’s other technical shows that its 14-day RSI now stands at 20. 94% Trade AZRX Now! Join SI Premium – FREE. A number of research firms have recently weighed in on AZRX. Nov 04, 2019 · The 52-week high is now at -73. 16) earnings per share for the current quarter, Zacks Investment Research reports. 11, 2019 at 7:50 a. 17% from its 52-Week high price while it is -14. 00 price target on AzurRx BioPharma and gave the stock a “buy” rating in a report on Tuesday, October 15th. Oct 17, 2018 · AzurRx BioPharma (NASDAQ:AZRX) initiated with Outperform rating and $6 (140% upside) price target at Oppenheimer. AZRX updated stock price target summary. Aug 19, 2019 4) Payment to Mayoly of 800,000 in shares of AZRX common stock report, AzurRx has achieved its enrollment target in the OPTION trial,  1 day ago H. 00 price objective on shares of AzurRx BioPharma and gave the company a “buy” rating in a research note on Tuesday, October 15th. SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. Dec 27, 2016 · Analysts at WallachBeth Capital have initiated coverage on AZRX shares with a “BUY” rating and a twelvemonth price target of $7. AzurRx specializes in non-systemic therapies focused on the micobiome and gastrointestinal diseases. DOW JONES, A NEWS CORP COMPANY News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for Apr 30, 2018 · BROOKLYN, N. 00 Update - September 27, 2017 - Buy - Price Target $4. and Japan Patents Covering a MTAN Inhibitor for Treating H. F2020E. A rating of 1 points to highest price growth (largest percent return), while a rating of 100 points to lowest price growth (smallest percent return). 18) for the current quarter, according to Zacks. The price of the stock the last time has raised by 88. Click to view NAQ:AZRX's StockReport 1H:17. Analyst price targets provided by TipRanks. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Stock discussion forums can often be a place of loud opinions and little merit. 77 distance from current price. AzurRx BioPharma Inc (NASDAQ:AZRX) was the target of a large growth in short interest during the month of November. 15) for the current fiscal quarter, according to Zacks. Jul. Short term moving average is currently above mid-term; AND below long term moving averages. To help users find value, the Tradescores forum requires participants to hold an open and filled position, either long or short, in the stock they are discussing. A look at the stock’s other technical shows that its 14-day RSI now stands at 71. The day’s price range saw the stock hit a low of $0. , AZRX stock construct a change of 8. Seeing some good reaction to good news posted recently. Our target price is $7. The average price target represents a 300. , April 30, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma (NASDAQ:AZRX), (“AzurRx” or the “Company”), announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Jan 01, 2020 · AzurRx BioPharma (AZRX) traded 390389 shares on hands and observed an average volume with 287. Nov 29, 2019 · AZRX was given a price target of $9, with other Wall Street analysts also giving their reports regarding the stock. Jan 30, 2018 · NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage on AzurRx BioPharma, Inc. 6%. 14) has crossed the mark of 70. Their recent low of $3. Bio-Techne (NASDAQ:TECH) initiated with Neutral rating and AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. New CEO. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term. (NASDAQ:AZRX) is going up by 31. The stock price has been seen performing along underground drift from its 200 days moving average with -3. 64%. The firm issued a buy rating and a $9. As a result of these changes our target price moves from $7. Wednesday, October 17, 2018. as it relates to AzurRx BioPharma, Inc. 83, 444,391 shares changed hands during trading. is looking more favorable than argenx SE, analysts belief. 56, close to its 52-week low of $0. azrx price target